5-Alpha Reductase Inhibitors and Prostate Cancer Mortality among Men with Regular Access to Screening and Health Care
Abstract
How 5-alpha reductase inhibitor (5-ARI) use influences prostate cancer mortality is unclear. The objective of this study was to determine whether men taking 5-ARIs with regular health care access have increased prostate cancer mortality.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 04, 2022
- Source ID
- 10.1158/1055-9965.epi-21-1234
Entities
People
- Adam S. Kibel
- Anna Plym
- Aria F. Olumi
- Carl Ceraolo
- Claire H. Pernar
- Edward L. Giovannucci
- Emily M. Rencsok
- Jane B. Vaselkiv
- Kathryn M. Wilson
- Konrad H Stopsack
- Lorelei A. Mucci
- Mark A. Preston
- Sydney T. Grob
Organizations
- Beth Israel Deaconess Medical Center
- Brigham and Women's Hospital
- Harvard Medical School
- Harvard University
- Karolinska Institutet
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute
- National Institutes of Health
- United States Department of Defense